Hesperidin ( DrugBank: Hesperidin )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
93	Primary biliary cholangitis	1

46. Malignant rheumatoid arthritis

---

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05756179 (ClinicalTrials.gov)	July 2023	21/2/2023	Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis	Clinical Study Evaluating the Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Diosmin and Hesperidin Combination	Alexandria University	NULL	Not yet recruiting	19 Years	65 Years	All	80	Phase 3	NULL

93. Primary biliary cholangitis

---

Clinical trials : 298 /  Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs051210210	30/03/2022	30/03/2022	BIG STEP	Benefit of glucosyl Hesperidin in patients with primary biliary cholangitis: amulticenter, open-label, randomized control study	Primary Biliary Cholangitis Cholangitis	Participants will be randomly assigned to standard dose and high dose groups. In standard dose group, hesperidin tablet 500 mg (two tablets at a time once a day after meal) will be orally administered for 24 weeks. In high dose group, hesperidin tablet 1000mg (four tablets at a time once a day after meal) will be orally administered for 24 weeks.	Fujinaga Hisayuki	NULL	Recruiting	>= 20age old	Not applicable	Both	110	Phase 2	Japan